Intalight has received a CE mark for its Dream OCT platform, allowing the company to commercialise the optical coherence tomography (OCT) device in Europe.
Dream stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. Intalight claims the imaging platform provides the highest quality OCT images currently on the market.
“Intalight is incredibly proud to receive CE mark approval in Europe for our Dream OCT,” said Intalight Chairman and Founder, Shawn Peng.
“This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients.”
In Australia, the device is expected to be launched at ODMAFair next month, pending approval from the Therapeutic Goods Administration (TGA).
Dream OCT can cover an ultra-widefield single scan, which delivers a 130° OCT-Angiography (OCT-A) image. It’s swept-source 12 mm super-depth scanning allows superior imaging of the choroid and retina, and a large portion of the vitreous space. The super-depth anterior scanning capabilities achieve 16.2 mm (in air), allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be scanned in only one scan. The longer wavelength allows for superior penetration through opacities in either lens or vitreous.
“Over the past few years, we’ve heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth,” said Intalight CEO and Co-Founder, Bing Li.
“Dream OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else ECPs know.”
In Australia, the device is expected to be launched at ODMAFair next month, pending approval from the Therapeutic Goods Administration (TGA).
